Compare · IMMX vs JNJ
IMMX vs JNJ
Side-by-side comparison of Immix Biopharma Inc. (IMMX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMMX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $537.39B, about 912.3x IMMX ($589.0M).
- IMMX has been more active in the news (17 items in the past 4 weeks vs 12 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 3 for IMMX).
- Company
- Immix Biopharma Inc.
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $589.0M
- $537.39B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 17
- 12
- Recent ratings
- 3
- 25
Immix Biopharma Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest IMMX
- Immix Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Chang Nancy T was granted 6,250 shares, increasing direct ownership by 1% to 428,190 units (SEC Form 4)
- SEC Form 4 filed by CFO, President Morris Gabriel S
- Director Adams Helen C. was granted 6,250 shares, increasing direct ownership by 4% to 181,004 units (SEC Form 4)
- Director Marquet Magda was granted 6,250 shares, increasing direct ownership by 14% to 52,342 units (SEC Form 4)
- Director Ng Carey was granted 6,250 shares, increasing direct ownership by 31% to 26,250 units (SEC Form 4)
- Director Chudnovsky Yekaterina was granted 6,250 shares (SEC Form 4)
- Director Buchan Jane was granted 6,250 shares, increasing direct ownership by 28% to 28,705 units (SEC Form 4)
- SEC Form 4 filed by CEO and Chairman Rachman Ilya M
- Director Hsu Jason was granted 6,250 shares, increasing direct ownership by 0.70% to 899,250 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target